During the last session, Nuvation Bio Inc (NYSE:NUVB)’s traded shares were 1.3 million, with the beta value of the company hitting 1.45. At the end of the trading day, the stock’s price was $1.88, reflecting an intraday loss of -3.09% or -$0.06. The 52-week high for the NUVB share is $4.16, that puts it down -121.28 from that peak though still a striking 9.04% gain since the share price plummeted to a 52-week low of $1.71. The company’s market capitalization is $636.72M, and the average intraday trading volume over the past 10 days was 3.03 million shares, and the average trade volume was 2.56 million shares over the past three months.
Nuvation Bio Inc (NUVB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. NUVB has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.12.
Nuvation Bio Inc (NYSE:NUVB) trade information
Nuvation Bio Inc (NUVB) registered a -3.09% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.09% in intraday trading to $1.88, hitting a weekly high. The stock’s 5-day price performance is -5.05%, and it has moved by -8.29% in 30 days. Based on these gigs, the overall price performance for the year is -18.61%. The short interest in Nuvation Bio Inc (NYSE:NUVB) is 28.39 million shares and it means that shorts have 9.84 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 68.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $10 respectively. As a result, NUVB is trading at a discount of -431.91% off the target high and -165.96% off the low.
Nuvation Bio Inc (NUVB) estimates and forecasts
In the rating firms’ projections, revenue will increase 72.24% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 416.67k as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 416.67k by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -49.14%. While earnings are projected to return 73.12% in 2025, the next five years will return 37.20% per annum.
NUVB Dividends
Nuvation Bio Inc is due to release its next quarterly earnings on 2025-Mar-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
Nuvation Bio Inc insiders own 26.68% of total outstanding shares while institutional holders control 58.95%, with the float percentage being 80.41%. FMR LLC is the largest shareholder of the company, while 212.0 institutions own stock in it. As of 2024-06-30, the company held over 28.82 million shares (or 11.7767% of all shares), a total value of $84.16 million in shares.
The next largest institutional holding, with 19.21 million shares, is of ECOR1 CAPITAL, LLC’s that is approximately 7.8491% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $56.09 million.
Also, the Mutual Funds coming in first place with the largest holdings of Nuvation Bio Inc (NUVB) shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund . Data provided on Jan 31, 2025 indicates that Fidelity Growth Company Fund owns about 15.47 shares. This amounts to just over 4.58 percent of the company’s overall shares, with a $29.08 million market value. The same data shows that the other fund manager holds slightly less at 8.96, or about 2.65% of the stock, which is worth about $16.84 million.
